1. Home
  2. SBFG vs SPRO Comparison

SBFG vs SPRO Comparison

Compare SBFG & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SB Financial Group Inc.

SBFG

SB Financial Group Inc.

HOLD

Current Price

$23.25

Market Cap

136.9M

Sector

Finance

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.22

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBFG
SPRO
Founded
1983
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
136.9M
156.3M
IPO Year
2014
2017

Fundamental Metrics

Financial Performance
Metric
SBFG
SPRO
Price
$23.25
$2.22
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
24.3K
1.6M
Earning Date
04-23-2026
05-13-2026
Dividend Yield
2.98%
N/A
EPS Growth
27.33
111.81
EPS
0.69
N/A
Revenue
N/A
$66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$300.00
P/E Ratio
$33.96
N/A
Revenue Growth
N/A
39.24
52 Week Low
$18.05
$1.80
52 Week High
$25.05
$3.08

Technical Indicators

Market Signals
Indicator
SBFG
SPRO
Relative Strength Index (RSI) 61.76 42.65
Support Level $20.94 $2.14
Resistance Level $23.93 $2.52
Average True Range (ATR) 0.89 0.26
MACD 0.10 -0.06
Stochastic Oscillator 57.03 28.64

Price Performance

Historical Comparison
SBFG
SPRO

About SBFG SB Financial Group Inc.

SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in a single segment, which is Banking.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: